For: | Panyavaranant P, Manchana T. Preoperative markers for the prediction of high-risk features in endometrial cancer. World J Clin Oncol 2020; 11(6): 378-388 [PMID: 32874951 DOI: 10.5306/wjco.v11.i6.378] |
---|---|
URL: | https://www.wjgnet.com/2218-4333/full/v11/i6/378.htm |
Number | Citing Articles |
1 |
Kelechi Njoku, Chloe E. Barr, Emma J. Crosbie. Current and Emerging Prognostic Biomarkers in Endometrial Cancer. Frontiers in Oncology 2022; 12 doi: 10.3389/fonc.2022.890908
|
2 |
Chloe E. Barr, Kelechi Njoku, Eleanor R. Jones, Emma J. Crosbie. Serum CA125 and HE4 as Biomarkers for the Detection of Endometrial Cancer and Associated High-Risk Features. Diagnostics 2022; 12(11): 2834 doi: 10.3390/diagnostics12112834
|
3 |
Chloe E. Barr, Jamie C. Sergeant, Heather J. Agnew, James Bolton, Rhona J. McVey, Emma J. Crosbie. Serum HE4 predicts progestin treatment response in endometrial cancer and atypical hyperplasia: A prognostic study. BJOG: An International Journal of Obstetrics & Gynaecology 2023; 130(8): 941 doi: 10.1111/1471-0528.17417
|
4 |
Roya Behrouzi, Chloe E. Barr, Emma J. Crosbie. HE4 as a Biomarker for Endometrial Cancer. Cancers 2021; 13(19): 4764 doi: 10.3390/cancers13194764
|
5 |
K. Shawn LyBarger, Hunter A. Miller, Hermann B. Frieboes. CA125 as a predictor of endometrial cancer lymphovascular space invasion and lymph node metastasis for risk stratification in the preoperative setting. Scientific Reports 2022; 12(1) doi: 10.1038/s41598-022-22026-1
|
6 |
Sh. T. Ibadova. Structure of Hyperplastic Processes of the Uterus in Menopausal Women According to the Results of an Echographic Study. Ukraïnsʹkij žurnal medicini, bìologìï ta sportu 2022; 7(4): 36 doi: 10.26693/jmbs07.04.036
|
7 |
Yingsha Yao, Liujing Shi, Xiaoming Zhu. Serum Anti-Mullerian Hormone Levels Might Indicate Premenopausal Endometrial Lesions. Diagnostics 2023; 13(21): 3301 doi: 10.3390/diagnostics13213301
|
8 |
Li‐na Han, Yi‐wei Han, Ping Yan. Prognostic values of human epididymis protein 4 expression in patients with endometrial cancer: A systematic review and meta‐analysis. Journal of Obstetrics and Gynaecology Research 2022; 48(9): 2255 doi: 10.1111/jog.15356
|
9 |
X.N. Yue, X.Y. He, J.J. Wu, W. Fan, H.J. Zhang, C.W. Wang. Endometrioid adenocarcinoma: combined multiparametric MRI and tumour marker HE4 to evaluate tumour grade and lymphovascular space invasion. Clinical Radiology 2023; 78(8): e574 doi: 10.1016/j.crad.2023.04.005
|
10 |
Qiaoyan Lin, Yongwei Lu, Rong Lu, Yujuan Chen, Linghua Wang, Jianping Lu, Xianren Ye. Assessing Metabolic Risk Factors for LVSI in Endometrial Cancer: A Cross-Sectional Study. Therapeutics and Clinical Risk Management 2022; : 789 doi: 10.2147/TCRM.S372371
|
11 |
Hunter A. Miller, Anh Tran, K. Shawn LyBarger, Hermann B. Frieboes. A clinical marker-based modeling framework to preoperatively predict lymph node and vascular space involvement in endometrial cancer patients. European Journal of Surgical Oncology 2024; 50(1): 107309 doi: 10.1016/j.ejso.2023.107309
|
12 |
Anna Jagodzińska, Anita Chudecka-Głaz, Kaja Michalczyk, Ewa Pius-Sadowska, Sylwia Wieder-Huszla, Anna Jurczak, Bogusław Machaliński. The Diagnostic Role of FGF 21 in Endometrial Cancer and Other Pathologies of the Uterine Corpus. Diagnostics 2023; 13(3): 399 doi: 10.3390/diagnostics13030399
|
13 |
Caner KOSE, Büşra KÖRPE, Vakkas KORKMAZ, Yaprak USTUN. Preoperatif Belirteçlerin Endometriyal İntraepitelyal Neoplazi Hastalarında Endometriyum Kanserini Öngörmedeki Rolü. Türk Kadın Sağlığı ve Neonatoloji Dergisi 2022; 4(3): 128 doi: 10.46969/EZH.1136385
|
14 |
Xiaoning Yue, Xiaoyu He, Shuaijie He, Jingjing Wu, Wei Fan, Haijun Zhang, Chengwei Wang. Multiparametric magnetic resonance imaging-based radiomics nomogram for predicting tumor grade in endometrial cancer. Frontiers in Oncology 2023; 13 doi: 10.3389/fonc.2023.1081134
|